Close Menu

The Wall Street Journal reports on innovative approaches to getting people to enroll in clinical trials, including one that it describes as "a sort of medical matchmaker that is gaining wider usage: EmergingMed, a for-profit service that connects patients to cutting-edge clinical trials." Let's hope one of these programs works. While they may not realize it, consumers are an essential part of the biomedical enterprise and new treatments can't emerge without them.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.